JANX vs. PCVX, MTSR, KRYS, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, and ZLAB
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.
Janux Therapeutics vs. Its Competitors
Janux Therapeutics (NASDAQ:JANX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.
In the previous week, Vaxcyte had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Janux Therapeutics. Vaxcyte's average media sentiment score of 0.99 beat Janux Therapeutics' score of 0.79 indicating that Vaxcyte is being referred to more favorably in the news media.
Janux Therapeutics' return on equity of -11.48% beat Vaxcyte's return on equity.
Janux Therapeutics has higher revenue and earnings than Vaxcyte. Janux Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.
Janux Therapeutics currently has a consensus price target of $78.31, indicating a potential upside of 202.53%. Vaxcyte has a consensus price target of $106.25, indicating a potential upside of 135.34%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Vaxcyte.
Janux Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Janux Therapeutics beats Vaxcyte on 11 of the 15 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:JANX) was last updated on 10/13/2025 by MarketBeat.com Staff
